Skip to main content

Facilitating Collaborations to Develop Combination Investigational Cancer Therapies Workshop Summary (2012) / Chapter Skim
Currently Skimming:

8 Codevelopment of Therapies for HIV as a Model
Pages 63-68

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 63...
... "Within a single individual shortly after infection, there are essentially millions of variants, so like for cancer therapy, where the cancer cells are constantly mutating, combinations for us are very important." In 1996, three agents were successfully combined to treat HIV after they were shown to induce rapid reduction of viral loads and led to sustainable undetectable levels of virus in the blood. Since then, the entire field of therapeutics has focused on optimizing these combinations for safety, tolerability, and dosing.
Read the entire page →
From page 64...
... Dieffenbach stressed. THE IMPORTANCE OF SURROGATE MARKERS HIV drug development benefited immensely from the ability to use viral load as a validated surrogate for response to therapy, Dr.
Read the entire page →
From page 65...
... The grey shaded area is the estimated range of average IIP values needed to stop viral replication in a patient with a viral load of 30,000 copies/milliliter. Only one drug, darunavir, may likely halt viral replication without a combination.
Read the entire page →
From page 66...
... THE KEY ROLE OF PATIENT ADVOCATES Another lesson learned from HIV combination therapy development that may be applicable to the development of cancer combination thera pies is the key role patient advocates played in fostering collaborations, Drs. Dieffenbach and Nabel pointed out.
Read the entire page →
From page 67...
... Dr. Nabel added that there were specific granting mechanisms that promoted development in certain areas, including the NCDDG Program (National Cooperative Drug Discovery Groups)
Read the entire page →

Key Terms

  • combination therapies
  • combination therapy
  • patient advocates
  • drug development
  • combination vaccines

  • cancer therapy
  • viral replication
  • viral load
  • hiv drug
  • hiv vaccines

  • average iip
  • nabel added
  • inhibitory potential
  • antiretroviral drugs
  • third type

  • cancer combination
  • pharmaceutical companies
  • fundamental difference
  • stop viral
  • similar approach

  • cer arena
  • drug discovery
  • joins drug
  • neither treatment
  • combination treatment

  • difference scientifically
  • loud voice
  • undetectable levels
  • invite advocates
  • help provide


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.